The Next Great Cosmetic Drug?

This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including more biotech buyout rumors, a hot new biotech start-up, and a new cosmetic drug.

In this video, health-care analyst David Williamson discusses a potential new solution to the double chin. Shares of Kythera (Nasdaq; KYTH) soared 25% on the news of a successful phase 3 trial for ATX-101, the sole drug in its pipeline.

Watch Market Checkup and find out more about the exciting cosmetic drug space, including a closer look at Botox maker Allergan (NYSE: AGN  ) , and whether investors should jump aboard the Kythera bandwagon. 

Stocks for a wealthy retirement
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Follow David on Twitter: @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2657398, ~/Articles/ArticleHandler.aspx, 4/16/2014 9:42:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement